Navigation Links
Cynosure Announces Preliminary Financial Results for the First Quarter of 2009
Date:4/15/2009

Company Further Reduces 2009 Operating Expenses to Address Continued Industry Weakness;

Cynosure to Report First-Quarter 2009 Financial Results on Tuesday, May 5

WESTFORD, Mass., April 15 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced preliminary, unaudited financial results for the quarter ended March 31, 2009.

Reflecting continued softness in the aesthetic laser industry, Cynosure expects first-quarter 2009 revenues to be in the range of $14 million to $15 million, compared with revenues of $36.8 million in the first quarter of 2008. The company expects to report a GAAP net loss for the first quarter of 2009 of $3.8 million to $4.3 million, or $0.30 to $0.34 per share, compared with GAAP net income of $4.9 million, or $0.38 per diluted share, for the three months ended March 31, 2008.

"The global economic recession continued to negatively affect our business throughout the first quarter, which historically has been our weakest quarter of the year," said Cynosure President and Chief Executive Officer Michael Davin. "While we experienced pockets of order strength in the first quarter, particularly in March, overall aesthetic laser capital equipment spending was down significantly. We attribute this decline to the continued restrictive credit environment and general caution among aesthetic practitioners and consumers, who remain uncertain about the duration of this economic downturn."

"We are continuing to adjust our operating expenses in response to the current market conditions and reduced revenue levels," Davin said. "In recent weeks we have cut an additional 25 positions from our worldwide workforce. This reduction has been partially offset by the opening in February of our direct sales office in Korea and the associated hiring of 11 employees, bringing our current total worldwide headcount to 271 employees. In addition, we have continued to reduce our planned spending for various programs in 2009. Overall, we expect our cost-reduction initiatives this year to produce an annualized operating expense savings to Cynosure of approximately $14 million to $18 million, which exceeds the projected $8 million to $10 million in savings we forecasted earlier in the year."

"While the global recession has created some significant near-term hurdles for our industry, we remain committed to the steps we believe are central to our long-term success," Davin said. "Over the past several years, our emphasis on technology innovation, product development and strong distribution has enabled us to grow into one of the industry's largest companies. We have benefitted from positive momentum on the scientific front, as evidenced by the Smartlipo MPX data presented recently at the American Society for Laser Medicine and Surgery Annual Conference. In the quarters ahead, we will continue to focus on aligning our expenses with our revenue levels, while working to maintain our technology and product position. It remains our goal to manage the business profitably in 2009."

Company to Host First-Quarter 2009 Conference Call on May 5

Cynosure plans to announce its financial results for the quarter ended March 31, 2009 before the opening of the market on Tuesday, May 5 and host a conference call that day at 9:00 a.m. ET.

Those who wish to listen to the conference call webcast should visit the "Investor Relations" section of the company's website at www.cynosure.com. The live call also can be accessed by dialing (877) 407-5790 or (201) 689-8328. If you are unable to listen to the live call, the webcast will be archived on the company's website.

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the company's preliminary results for the first quarter of 2009, ability to reduce expenses or expectations regarding future results, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the global economic recession and its effects on the aesthetic laser industry, Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, and economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

    Contact: 

    Scott Solomon
    Vice President
    Sharon Merrill Associates, Inc.
    617.542.5300
    cyno@investorrelations.com


'/>"/>
SOURCE Cynosure, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CoolTouch Inc. Settles Diomed Lawsuit, Files Re-examination Request for Cynosure 873 Patent
2. Cynosure Obtains Favorable Markman Rulings in Patent Infringement Case Against CoolTouch
3. Cynosure Appoints William T. Kelley as Senior Vice President of International Sales
4. Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008
5. Cynosure to Announce Fourth-quarter and Full-year 2008 Financial Results on February 10
6. Cynosure Provides Preliminary Financial Results for the Fourth Quarter of 2008
7. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
8. Cynosure to Announce Second-Quarter 2008 Financial Results on July 29
9. Cynosure President and CEO Michael Davin Named Ernst & Young Entrepreneur of the Year(R) 2008 Award Winner in New England
10. Cynosure Expands Presence in China with the Opening of Sales Office in Beijing
11. Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology: